In the subsequent multivariate analysis, female gender (OR = 4.78; 95% CI = 1.22–20.63), presence of allergies (OR = 4.02; 95% CI = 1.05–16.73), and FCER1B rs569108-AA genotype (OR = 11.51; 95% CI = 1.19–269.78) were identified as independent variables associated with a reduction in OCS after 12 months of benralizumab treatment (see Table 4). Here, MS4A2 is linked to allergic disease.